BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 25318595)

  • 1. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvants for cancer vaccines.
    Dubensky TW; Reed SG
    Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
    Tefit JN; Serra V
    Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
    Kobiyama K; Ishii KJ
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic cancer vaccines: a long and winding road to success.
    Baxevanis CN; Papamichail M; Perez SA
    Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Various ways to improve whole cancer cell vaccines.
    Cicchelero L; de Rooster H; Sanders NN
    Expert Rev Vaccines; 2014 Jun; 13(6):721-35. PubMed ID: 24758597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges facing adjuvants for cancer immunotherapy.
    Mesa C; Fernández LE
    Immunol Cell Biol; 2004 Dec; 82(6):644-50. PubMed ID: 15550123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE
    Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current challenges for cancer vaccine adjuvant development.
    Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
    Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.